SEARCH
YOUR SEARCH FOR Text 15 RESULTS
1 of Total
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 | Incyte
… October 26, 2026 at 9:45 AM EDT PDF Version INCB161734 (KRAS G12D inhibitor) and INCA33890 1 … cancer (CRC), respectively New data evaluating INCB161734 in CRC highlight its clinical …
Read More
2 of Total
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer | Incyte
… EDT PDF Version Phase 1/2 study will evaluate INCB161734 plus petosemtamab and … a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and …
Read More
3 of Total
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ES
… presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA33890 … on rapid oral presentations at ESMO include: INCB161734 (KRAS G12D) Safety and Efficacy of …
Read More
4 of Total
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates | Incyte
… the initiation of a Phase 3 trial evaluating INCB161734 in pancreatic ductal adenocarcinoma … locally advanced Merkel cell carcinoma (MCC). INCB161734 (KRASG12D) The Company initiated a …
Read More
5 of Total
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates | Incyte
… study are anticipated in early 2029. Oncology INCB161734 (KRASG12D) The Phase 3 study (DAWN-303) evaluating INCB161734 as a first-line treatment in patients …
Read More
6 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… 2024 highlighting its KRASG12D inhibitor (INCB161734). INCB161734 is a potent, selective, and orally …
Read More
7 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… results from the Phase 1 trial evaluating INCB161734 (KRAS G12D selective inhibitor) were … at the ESMO Congress in October. In the trial, INCB161734 demonstrated a manageable safety …
Read More
8 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
… ovarian cancer is anticipated in 2026. INCB161734 (KRAS G12D ) In January 2026 , clinical data from a Phase 1 trial evaluating INCB161734 in patients with advanced/metastatic …
Read More
9 of Total
Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology & Inflammation and Autoimmunity
… 3 TGFßR2×PD-1 Solid tumors status for mobile INCB161734 KRAS G12D KRAS G12D-mutated PDAC status for mobile INCB161734 KRAS G12D KRAS G12D-mutated solid …
Read More
10 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… patients. A Phase 1 study of KRASG12D (INCB161734) in patients with advanced metastatic … Amplification/ Overexpression of CCNE1: Phase 1 INCB161734 ( KRASG12D)   Advanced metastatic …
Read More